Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Alpha-Particle Radiopharmaceuticals Moving Forward as AML Therapy

September 8th 2014

Although standard induction therapy produces complete remissions in 50% to 70% of patients with acute myeloid leukemia (AML), long-term survival is seen in only 20% to 40% of patients. The prognosis for older patients is even worse, with a 5-year survival rate of 5% for patients older than 65 years.

Chimeric Antigen Receptor (CAR) T-Cell Immunotherapy for Leukemia and Beyond

August 29th 2014

Chimeric antigen receptor T-cell therapy is an immunotherapy in which the patient's own T cells are isolated in the laboratory, redirected with a synthetic receptor to recognize a particular antigen or protein, and reinfused into the patient.

Dr. Younes on Brentuximab Plus AVD vs ABVD in Classical Hodgkin Lymphoma

August 28th 2014

Anas Younes, MD, chief, Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses the ongoing Echelon-1 study in classical Hodgkin lymphoma.

Dr. Sawyer on LBM Outcomes With Siltuximab in Multicentric Castleman's Disease

August 26th 2014

Michael Sawyer, MD, associate professor, Medical Oncology, University of Alberta, discusses lean body mass (LBM) outcomes in patients with multicentric Castleman's disease who received siltuximab (Sylvant).

Dr. Flinn Discusses IPI-145 as Potential Treatment for Hematologic Malignancies

August 26th 2014

Ian W. Flinn, MD, PhD, director, Hematologic Malignancies Research Program, Sarah Cannon Research Institute, discusses IPI-145, an oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K- gamma.

Dr. Flynn on Obinutuzumab for the Treatment of CLL

August 25th 2014

Joseph M. Flynn, DO, MPH, discusses the results of the phase II GAGE study, which compared 1000 mg vs 2000 mg of obinutuzumab in patients with chronic lymphocytic leukemia (CLL).

Lenalidomide Plus R-CHOP Effective in Aggressive DLBCL Subtype

August 19th 2014

The addition of lenalidomide to R-CHOP demonstrated promising efficacy in previously untreated patients with diffuse large B-cell lymphoma across all subtypes of the disease.

International Hematology/Oncology Elective: A Unique Learning Experience

August 14th 2014

Although minor institution-specific variations exist, traditional fellowship programs in the United States are able to provide training in the sophisticated Western style of practice.

Attacking Acquired Mutations: Researchers Aim to Make Molecularly Targeted Cancer Therapies "Smarter"

August 8th 2014

Hailed as "new ammunition in the war against cancer" and featured in TIME magazine at the turn of the new millennium, molecularly targeted therapies have gone on to revolutionize cancer treatment. Clinical responses, however, are all too often short-lived as cancer cells become resistant.

FDA Grants Priority Review to Ruxolitinib in Polycythemia Vera

August 5th 2014

The FDA has assigned a priority review designation to the JAK1/2 inhibitor ruxolitinib as treatment for patients with polycythemia vera who are resistant or intolerant to hydroxyurea

Carfilzomib Combination Effective for Relapsed Myeloma

August 4th 2014

The combination of carfilzomib (Kyprolis), lenalidomide (Revlimid), and low-dose dexamethasone extended progression-free survival (PFS) by 8.7 months compared with lenalidomide and dexamethasone alone for patients with relapsed multiple myeloma

FDA Expands Ibrutinib's CLL Approval

July 28th 2014

The FDA has expanded the approval of ibrutinib to include the treatment of patients with chronic lymphocytic leukemia who have received at least one previous therapy and harbor a 17p deletion.

Dr. Flynn Discusses Ibrutinib for Hematologic Malignancies

July 28th 2014

Joseph M. Flynn, DO, MPH, co-director, Division of Hematology; co-director, LIVESTRONG Survivorship Center of Excellence; medical director, James Survivorship Clinics, The Ohio State University, James Cancer Hospital, discusses the impact ibrutinib has had on treating hematologic malignancies.

Ruxolitinib Outperforms Standard Therapy in Polycythemia Vera

July 24th 2014

In the first pivotal phase III study of a Janus-associated kinase (JAK) inhibitor for the treatment of polycythemia vera (PV), ruxolitinib (Jakafi) was superior to best available therapy (BAT) in maintaining control of hematocrit without the need for phlebotomy and in reducing spleen size in patients with an inadequate response to or intolerance of hydroxyurea.

FDA Approves Idelalisib for CLL, SLL, and Follicular Lymphoma

July 23rd 2014

The FDA has approved idelalisib in combination with rituximab for patients with high-risk relapsed or refractory CLL and as a single-agent for two types of iNHL.

ASCO 2014: Gearing Up for More Changes

July 21st 2014

The ASCO annual meeting is always a time of excitement for the nearly 30,000 clinicians and scientists who gather every year to see "what's new."

IDH2 Inhibitor Shows Promise in AML

July 18th 2014

An early study presented at the 2014 AACR Annual Meeting showed promise for a new targeted therapy for acute myeloid leukemia

CLL Researcher Excited About Outlook for CDK Inhibitors

July 17th 2014

Joseph Flynn, DO, MPH, focuses on the development of novel therapeutics for the treatment of chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL) in his research at The Ohio State University Comprehensive Cancer Center.

First CAR Therapy Receives FDA Breakthrough Designation

July 8th 2014

The investigational CD19-targeted CAR therapy CTL019 has received a breakthrough therapy designation from the FDA as a potential treatment for pediatric and adult patients with relapsed/refractory ALL.

FDA Approves Belinostat for Peripheral T-Cell Lymphoma

July 3rd 2014

The FDA has approved belinostat for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma.